SEC Form 4 · accession 0001179110-15-000492
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Chairman and CEO · Director
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 4:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2015 | M | 150,000 | $14.5025 | A | 4,272,987 | D | |
| Common StockF3 | Jan 2, 2015 | S | 132,200 | $95.0075 | D | 4,140,787 | D | |
| Common StockF4 | Jan 2, 2015 | S | 17,700 | $95.917 | D | 4,123,087 | D | |
| Common Stock | Jan 5, 2015 | S | 100 | $96.65 | D | 4,122,987 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock option (right to buy)F2 | $14.5025 | Jan 2, 2015 | M | 150,000 | D | — | Jan 25, 2016 | Common Stock | 150,000 | 1,650,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $94.590 to $95.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $95.62 to $96.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.